Thelansis

Surfactant Protein B (SP-B) Deficiency Market Outlook Thelansis’s “Surfactant Protein B (SP-B) Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Surfactant Protein B (SP-B) Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have th...

  Surfactant Protein B (SP-B) Deficiency Market Outlook Thelansis’s “Surfactant Protein B (SP-B) Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Surfactant Protein B (SP-B) Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Surfactant Protein B (SP-B) Deficiency Overview Surfactant protein B (SP-B) deficiency is an inherited disease of full-term newborn infants that leads to lethal respiratory failure within the first year of life. Genetic analysis of affected infants has permitted the identification of a mutation in the SP-B gene found in several unrelated kindreds, which disrupts pulmonary surfactant compos...